0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > -

-

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
ALPP/ALPPL2 mAb - 01 PCC Solid Tumor Endometrial cancer,Ovarian cancer
BCMA VHH - 01 Lead Hematological Malignancy Multiple myeloma
CCR8 mAb - 01 PCC Solid Tumor Solid tumor
CCR8 mAb - 02 Lead Solid Tumor Solid tumor
CCR8 mAb - 03 PCC Solid Tumor Solid tumor
CD25 mAb - 01 PCC Solid Tumor Solid tumor
CDH17 mAb - 01 PCC Solid Tumor Colorectal cancer,Gastric Cancer
CXCR4 mAb - 01 Lead Hematological Malignancy,AutoImmunity Blood tumor,Solid tumor

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
NGF mAb Monospecific antibody Neurological disease Cancer pain Phase II Global  (except China)
5-HT1F agonist Small molecule Neurological disease Migraine Phase I Global
TNFα and TGF-β1 inhibitor Small molecule Respiratory disease IPF Phase II Global  (except China)
Capsid Assembly Inhibitors for HBV Small molecule Infectious and parasitic diseases HBV Phase III Global  (except China)
PI3Kδ inhibitor Small molecule Oncology/Cancer Hematologic malignancies Phase I Global
Capsid Assembly Inhibitors for HBV Small molecule Infectious and parasitic diseases HBV Phase I Global  (except China)
RET high selective inhibitor Small molecule Oncology/Cancer NSCLC,Medullary thyroid cancer,Thyroid cancer Phase I Global
A SSRI & Partial 5-HT1A Agonist Small molecule Neurological disease Depression Phase III Global
sGC stimulator Small molecule Cardiovascular PAH,CTEPH,HFrEF,CKD Phase I Global
SGLT2 inhibitor Small molecule Metabolic disease Diabetes Phase III Global  (except China)
FXR Agonist Small molecule Metabolic disease Diabetic kidney disease Phase I Global
ACC inhibitor treating NASH Small molecule Metabolic disease NASH IND Global
Oxazolidone (new compounds) antibiotics Small molecule Infectious and parasitic diseases gram-positive bacterial infections IND Global
HIF-PHs inhibitor for CKD and Renal anemia Small molecule Blood and Clotting disease CKD,Renal anemia Phase I Global  (except China)
PI3K/mTOR dual inhibitor Small molecule Oncology/Cancer,Respiratory disease IPF,solid tumor Phase I Global  (except China)
Modified vilazodone Small molecule Neurological disease Major Depressive Disorder BE Global
CLDN 18.2 CAR-T Cell therapy Oncology/Cancer Gastric Cancer,Pancreatic Cancer IND Global
EpCAM CAR-T Cell therapy Oncology/Cancer Colorectal Cancer,Gastric Cancer,Other Cancer IIT Global
PI3Kδ inhibitor Small molecule Oncology/Cancer Advanced solid tumors Phase I Global
PARP inhibitor Small molecule Oncology/Cancer Advanced malignant solid tumors Phase I Global
Liver-Targeting THR-β Agonist Small molecule Metabolic disease Nonalcoholic Steatohepatitis (NASH) Phase I Global
PI3Kδ inhibitor Small molecule Oncology/Cancer Solid tumor,Hematological malignancies PCC Global
Best-in-class IRAK4 Degrader Immunological disease Psoriasis/RA/Inflammatory bowel disease (IBD)/autoimmune inflammatory diseases PCC Global
Best-in-class BCL-XL PROTAC Ophthalmology disease diabetic macular edema/diabetic retinopathy Preclinical Global
Novel Target Small Molecule Inhibitor for Heart Failure Cardiovascular Chronic heart failure IND Global
GPCR selective agonist Immunological disease Duchenne muscular dystrophy/Systemic lupus erythematous;/Ulcerative colitis;/Ankylosing spondylitis PCC Global
PD-1/IL-2Rβγ biased bifunction fusion protein Oncology/Cancer Gastric cancer/Pancreatic cancer/Lung cancer/Colorectal cancer Phase I Global
EGFR/cMet ADC Oncology/Cancer Gastric cancer/Pancreatic cancer/Colorectal cancer/ Lung cancer IND Global

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

DB-02-MALS-HPLC
 - ELISA

2% serum diluted by Dilution Buffer : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 2.383 and 2.148; 2% serum diluted by DB-02 : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 0.262 and 0.263. In the existence of DB-02, the serum background values significantly decreased. Note: Dilution Buffer is Wash Buffer with 0.5% (w/v) bovine serum albumin (BSA), 50 mL.

This web search service is supported by Google Inc.

totop

Laisser un message